Herein we report a strategy for the rapid and rational characterisation of novel microbial natural products from silent gene clusters. A conserved set of five regulatory genes was used as a query to search genomic databases and identify atypical biosynthetic gene clusters (BGCs). A 20-kb BGC from the genetically intractable Streptomyces sclerotialus bacterial strain was captured using yeast-based homologous recombination and introduced into validated heterologous hosts. CRISPR/Cas9-mediated genome editing was then employed to rationally inactivate the key transcriptional repressor and trigger production of an unprecedented class of hybrid natural products exemplified by (2-(benzoyloxy)acetyl)-L-proline, named scleric acid. Subsequent rounds of CRISPR/Cas9-mediated gene deletions afforded a selection of biosynthetic gene mutant strains which led to a plausible biosynthetic pathway for scleric acid assembly. Scleric acid and a key biosynthetic intermediate were also synthesised and used as authentic standards.
While actinomycete bacteria have been the foremost producers of antibiotics since the mid-1940s, in the last decade high-throughput DNA sequencing technologies and novel bioinformatics tools have highlighted an immense number of uncharacterised biosynthetic gene clusters (BGCs) predicted to direct the assembly of bioactive natural products. 1 The presence of BGCs was not only revealed in actinomycete genomes but also in those of human commensal and pathogenic bacteria (i.e. Staphylococcus lugdinensis, Burkholderia cepacia complex) as well as in the genomes of unculturable bacteria and in diverse metagenomic libraries. [2] [3] [4] [5] [6] Despite the conspicuous number of specialised metabolites isolated from actinomycetes, only a small fraction of the natural products 'encrypted' at the DNA level has been exploited to date.
Experimental characterisation of the biosynthetic product of a BGC is often laborious and timeconsuming particularly due to the uniqueness of every microorganism. Protocols for introducing DNA into bacterial cells are species-dependent and often ineffective. Their optimisation can take years but many culturable micro-organisms remain genetically intractable. In any case the vast majority of bacteria is genetically intractable as they are still unculturable in the laboratory environment thus preventing the exploitation of BGCs using many of the previously reported strategies. 1, 7 In addition, the biosynthesis of specialised metabolites is often tightly controlled at the transcriptional level. Cluster-associated transcriptional regulators that belong to the TetRfamily of transcriptional repressors are particularly numerous. 8 Deletions of cluster-specific TetR-like transcriptional repressors have been shown to trigger overproduction of the corresponding specialised metabolites, as seen for the antibiotics methylenomycin and coelimycin in Streptomyces coelicolor A3(2) and for the urea-containing gaburedins in Streptomyces venezuelae. [9] [10] [11] [12] Genetic manipulations of Streptomyces genomes has classically been accomplished using established but often laborious protocols optimised for a specific bacterial strains. 13 In recent years however, targeted genome editing has been revolutionised by the advent of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems, which allow for generating clean genomic deletions/insertions. 14 Toolkits for editing streptomycete genomes have been developed, [15] [16] [17] enabling researchers to overcome the issues associated with classical methods of gene disruption, in particular when multiple mutation events are desirable. The number of available selectable markers and issues with potential restoration of the wild-type configuration due to occurrence of single-crossover events were notable limitations.
Here, we report a strategy for selecting atypical BGCs and for rapid and rational characterisation of the corresponding natural products. The BGC is first captured and transferred into a validated heterologous host where CRISPR/Cas9-mediated genome editing can be employed to efficiently de-repress the expression of silent BGCs (Fig. 1 ).
We applied this approach for the identification, isolation and structural elucidation of a novel structural class of natural products from a silent and cryptic gene cluster found in the soil-dwelling species Streptomyces sclerotialus NRRL ISP-5269, a species of filamentous bacteria first isolated in Poona (India). 18 Beyond the discovery of this specialised metabolite, we strongly believe our approach will accelerate future research aimed at the characterisation of cryptic gene clusters from genetically intractable bacterial species or even from metagenomes.
Results

Identification of the scl gene cluster in S. sclerotialus NRRL ISP-5269
The prioritisation of the gene cluster under study was guided by the presence of a specific set of five regulatory genes that we had previously characterised and exploited to trigger the expression of a silent and cryptic biosynthetic gene cluster in Streptomyces venezuelae. 12 A Multigene BLAST 19 search was undertaken using as a query the DNA sequences of the following five genes: mmyR, mmfR (both code for TetR-like transcriptional repressors) and mmfLHP, responsible for the biosynthesis of signalling molecules, known as methylenomycin furans (MMF) that trigger production of the methylenomycin antibiotics in S. coelicolor A3(2). 9 In previous studies we have shown that inactivation of the mmyR-like transcriptional repressors is an effective approach for de-repressing silent gene clusters in actinomycetes. [10] [11] [12] Consequently, orthologues of the methylenomycin transcriptional regulators and their associated regulatory proteins were identified. Among the hits generated, the gene cluster from S. sclerotialus NRRL ISP-5269, named hereafter scl cluster, was chosen for further study; the nucleotide sequence containing the scl cluster was available from the GenBank accession number JOBC01000043.1. In addition to homologues of the five genes used as query, the genetic organisation of the scl gene cluster included two adjacent and divergent operons of biosynthetic genes ( Fig. 2a ). A combination of AntiSMASH 20 and manual BLASTp 19 analyses indicated the putative borders of the scl cluster ( Fig. 2a and Table 1 ). The predictive power of these modern bioinformatics tools often permits to deduce the chemical structure(s) of cryptic gene cluster product, particularly when modular systems such as type I modular polyketide synthases (PKS) or non-ribosomal peptide synthetases (NRPS) direct the biosynthesis. 22 However, the originality of the scl cluster prevented such predictions and we worked on the assumption that a lack of bioinformatics prediction was more likely to result in a more structurally diverse and therefore truly novel natural product. The cluster spanned a region of 19,782 bp, and comprised 18 putative genes: 11 biosynthetic genes, 6 genes for regulation and 1 gene coding for a membrane transporter ( Fig. 2a and Table 1 ).
Capture of the scl gene cluster and introduction into heterologous hosts
Introduction of plasmid DNA into S. sclerotialus NRRL ISP-5269 was attempted via intergenic-conjugation of mycelia with E. coli ET12567/pUZ8002 or protoplast transformation but these processes were found ineffective. 13 The preparation of S. sclerotialus NRRL ISP-5269 spores was also attempted but despite screening various culture media in the aim to induce sporulation, this strain showed little aerial growth.
We therefore set out to capture and heterologously express the scl gene cluster, with the aim of characterising its biosynthetic product(s) in a more genetically amenable host. A 33-kb region of genomic DNA that included the 19.7-kb scl BGC was captured from the purified genomic DNA of S. sclerotialus ISP-5269 via transformation-associated recombination (TAR) cloning. 23 A pCAP03-derived plasmid was first assembled to specifically recombine in yeast with both extremities of the 33-kb target DNA fragment. 24 The pCAP03-scl construct was introduced and stably integrated into the genome of Streptomyces albus J1074 and S. coelicolor M1152 via intergenic tri-parental conjugation with E. coli ET12567/pCAP03-scl and E. coli ET12567/pUB307. In parallel, the negative control strains S. albus/pCAP03 and S. coelicolor M1152 /pCAP03 were generated using the "empty" pCAP03 plasmid. The four Streptomyces strains were grown on supplemented minimal agar medium for 5 days, and the acidified agar medium was extracted with ethyl acetate. Their metabolic profiles were analysed by ultra-high pressure liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS). Comparison of the MS chromatograms failed to reveal any new compounds in the heterologous hosts where the scl BGC had been integrated.
De-repression of the scl gene cluster and characterisation of scleric acid
The lack of accumulation of novel metabolites in the scl-containing strains was likely to be due to the transcriptional repression activity of the TetR-like regulators encoded in the scl cluster. We had previously shown that genetic inactivation of mmyR-like genes in S. coelicolor A3(2) and in S. venezuelae would specifically de-repress the expression of adjacent BGCs. 10, 12 We therefore decided to genetically inactivate the mmyR homologous gene, sclM4 using the CRISPR/Cas9-based plasmid pCRISPomyces2 (pCm2). 15 For this purpose, we assembled the plasmid pCm2-sclM4 and attempted intergenic-conjugation of S. albus/scl and S. coelicolor M1152/scl with E. coli ET12567/pUZ8007/pCm2-sclM4. Ex-conjugants for strain S. albus/scl ∆sclM4 (see In order to establish the stereochemistry of the proline residue, scleric acid was hydrolysed and derivatised with Marfey's reagent. 25 L-and D-proline were also derivatised using the same procedure and used as standard for HPLC comparison.
Approximately 95% of the proline residue of scleric acid purified from S. albus/scl ∆sclM4 was found to correspond to L-proline ( Supplementary Fig. S7 ).
To confirm the proposed structure of scleric acid, an authentic standard was synthesised.
A structural analogue, with the three building blocks rearranged and possibly consistent with the initial NMR data obtained, was also synthesised (Supplementary Figs. S8-12).
LC-MS analyses and NMR data of both of these compounds unequivocally confirmed the proposed structure for scleric acid; the analogue revealed different NMR spectra and its physico-chemical properties resulted in a different retention time on LC-MS.
Defining key biosynthetic genes in the scl cluster
BLASTp analyses 19 combined with the elucidated structure for scleric acid allowed us to propose plausible functional assignments for all the biosynthetic enzymes coded in the scl BGC (Table 1) . [26] [27] [28] SclQ1-4 showed high homology to a set of three enzymes -QncN, QncL and QncMfrom Streptomyces melanovinaceus. This set of enzymes has been shown to direct the biosynthesis and attachment of a C 2 -glycolicacyl unit to a NRP. 28 SclA showed high similarity to anthranilate synthase enzymes, and together with SclD (putative DAHP synthase) and SclI (putative isochorismatase) was hypothesised to be responsible for biosynthesis of the benzoyl group found in scleric acid via chorismate as an intermediate.
SclN was predicted to be a non-ribosomal peptide synthetase (NRPS) enzyme consisting of a single minimal elongation module: a putative, atypical condensation domain (C), an adenylation domain (A) and a peptidyl carrier protein (PCP) domain. 29 The SclN Adomain was predicted to specifically activate L-proline, which was in accordance with the presence of a L-proline residue in scleric acid. 21 The SclN C-domain was proposed to catalyse the amide bond formation between L-proline and glycolic acid.
The role of SclN, SclA, and SclQ1-4 in the biosynthesis of scleric acid was investigated by constructing gene deletion mutants in strains where the transcriptional repressor sclM4 has also been inactivated (S. albus/scl ∆sclM4 background). Plasmids pCm2-sclN, pCm2-sclA and pCm2-sclQ1-4 were assembled and used to generate double mutant strains S. albus/scl ∆sclM4 ∆sclN, S. albus/scl ∆sclM4 ∆sclA and S. albus/scl ∆sclM4 ∆sclQ1-4. Deletions were confirmed by PCR screening ( Supplementary Fig.   S13 ). UHPLC-HRMS analysis revealed that production of scleric acid was abolished in S. albus/scl ∆sclM4 ∆sclN and S. albus/scl ∆sclM4 ∆sclA (Fig. 3a) , confirming the essential role of SclN and SclA. Residual scleric acid production was detected from S. albus/scl ∆sclM4 ∆sclQ1-4; this could be explained by the fact that glycolic acid is known to be produced by Streptomyces species in particular for the biosynthesis of Nglycolylmuramic acid. 30 Addition of 5 mM glycolic acid to the culture medium of S. albus/scl ∆sclM4 ∆sclQ1-4 also resulted in scleric acid being produced in similar level to that observed with S. albus/scl ∆sclM4 ( Supplementary Fig. S14 ).
The identification of key precursors in scleric acid biosynthesis was also exploited to further increase the titres of scleric acid produced by S. albus/scl ∆sclM4. Enriching the culture medium with 5 mM L-proline, 5 mM benzoic acid or 5 mM glycolic acid significantly increased levels of scleric acid observed upon UHPLC-HRMS analysis of the ethyl acetate extracts compared to those observed with S. albus/scl ∆sclM4 grown on the standard supplemented minimal medium ( Supplementary Fig. S15 ).
Based on the predicted function of the scl biosynthetic genes, we therefore proposed a putative biosynthetic route to scleric acid as shown in Fig. 4 and described in the discussion.
Biological activity of scleric acid
The antimicrobial activity of scleric acid was assessed. Inhibitory activity against representatives of the ESKAPE panel of pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae was first screened but all strains appeared to be resistant to scleric acid, giving no observable MIC ( Supplementary Table S1 ).
Scleric acid was then tested for a broader range of pharmaceutically relevant bioactivities through the Eli Lilly Open Innovation Drug Discovery (OIDD) Program. In a single point (20 µM) primary assays, scleric acid showed moderate antibacterial activity against Mycobacterium tuberculosis (H37Rv), exhibiting a 32% inhibition on the growth of this strain.
Scleric acid showed modest inhibitory activity on the cancer-associated metabolic enzyme Nicotinamide N-methyltransferase (NNMT), whose overexpression is known to contribute to tumorigenesis. 31 NNMT catalyses the transfer of a methyl group from S-adenosyl-Lmethionine (SAM) to nicotinamide, generating S-adenosyl-L-homocysteine (SAH) and 1methylnicotinamide (MNAN). 31 Scleric acid showed, on a concentration response curve assay, IC 50 of 178.0 µM (NNMT MNAN) and 186.6 µM (NNMT SAH) (Supplementary Figure S16 ).
Specialised metabolites from actinomycete bacteria are one of the most valuable sources of novel antibiotics, as well as of other useful bioactive compounds employed in various fields, from human medicine to crop protection. High-throughput sequencing of bacterial genomes/metagenomes has become quick and inexpensive, and is unearthing a myriad of putative gene clusters that are awaiting to be characterised and exploited.
In this study, we developed a pipeline for rational characterisation of specialised metabolites from actinomycete genomes (Fig. 1) . Starting with the bioinformatics identification and selection of cryptic gene clusters containing a characterised regulatory system, a DNA fragment containing the entire gene cluster is then captured via TAR cloning and introduced in the genome of a validated heterologous host. Expression of the biosynthetic genes are then triggered through CRISPR/Cas9-mediated editing of the key mmyR-like transcriptional repressors. Analytical chemistry procedures are then undertaken to identify, isolate and characterise the new natural product(s), overproduced in the heterologous host. Finally, subsequent rounds of CRISPR/Cas9-mediated gene deletions target putative biosynthetic genes and afford mutant strains. In turn, a biosynthetic route to the novel natural products can be proposed.
Our approach was validated by the discovery of (2-(benzoyloxy)acetyl)-L-proline, named scleric acid, from the genome of the soil-dwelling filamentous bacterium Streptomyces sclerotialus NRRL ISP-5269. The gene cluster of interest (scl) was identified via Multigene BLAST analysis, using as query the five-gene regulatory cassette involved in regulation of biosynthetic gene expression for methylenomycin production in Streptomyces coelicolor A3(2). 10 The scl cluster was captured using TAR cloning and transferred into two different heterologous hosts: Streptomyces albus J1074
and Streptomyces coelicolor M1152. These two strains were chosen as they are well characterised chassis for heterologous expression of actinomycete gene clusters. 32, 33 While no novel metabolite was observed in either of the two hosts, CRISPR/Cas9mediated deletion of the sclM4 transcriptional repressor, homologous to the tetR-like repressor mmyR from the methylenomycin gene cluster, 10 was attempted in the heterologous hosts. Mutant strains of S. albus/scl were readily obtained, whereas S. coelicolor M1152/scl failed to return any ex-conjugants using the same approach. The inefficacy of pCRISPomyces2 to edit the genome of S. coelicolor was unclear, however alternative CRISPR/Cas9-based methods for editing of this model species have now been described in the literature. 16, 17 De-repression of the scl cluster upon inactivation of the TetR-like repressor SclM4 within S. albus/scl resulted in accumulation of a novel hybrid compound, named scleric acid. Two sets of NMR signals were observed for the purified natural product as well as for the synthetic standard and revealed that scleric acid existed as two different rotamers, trans-and cis-scleric acid (Fig. 3e and Fig. S2 ). This is consistent with literature data for synthetic N-benzoyl-L-proline methyl ester where a 4:1 mixture of the two rotamers was observed. 34 A second round of CRISPR/Cas9-based editing was undertaken on S. albus/scl ∆sclM4 to inactivate putative key biosynthetic genes. This work established that the nonribosomal peptide synthetase (NRPS) gene sclN and the anthranilate synthase-like gene sclA are essential for scleric acid assembly. Deletion of the four-gene operon sclQ1-4 did not completely abolish scleric acid production, which could be explained by the fact that Streptomyces species are known to produce glycolic acid by other means. 30 As expected enrichment of the culturing medium with the key biosynthetic precursors i.e. L-proline, benzoic acid and glycolic acid led S. albus/scl ∆sclM4 to produce scleric acid in higher titres than when cultured in the supplemented minimal medium ( Supplementary Fig. S15 ). The strategy of manipulating the pathway-specific transcriptional regulatory system also makes scleric acid production not reliant on a complex culture medium. Importantly the utilisation of supplemented minimal media does significantly facilitate the isolation of the natural product of interest.
Based on the predicted function of the Scl enzymes a plausible biosynthetic route to scleric acid was proposed (Fig. 4) . A glycolic acid unit is believed to be produced by In addition to the novel biochemistry this biosynthetic pathway offers, scleric acid has been shown to exhibit moderate antibacterial activity against M. tuberculosis, as well modest inhibition on the cancer-associated enzyme Nicotinamide N-methyltransferase (NNMT). We are currently investigating scleric acid bioactivity further through the Eli Lilly Open Innovation Drug Discovery (OIDD) Program.
In conclusion, the pipeline we developed represents a rational and rapid approach for the characterisation of novel microbial natural products and can be employed for the discovery of new metabolites from cryptic and silent gene clusters that originate from genetically-intractable or pathogenic bacterial species.
Methods
Bioinformatics analysis
The whole genome sequence of Streptomyces sclerotialus NRRL ISP-5269 was 
Reagents
All chemicals were purchased from Sigma-Aldrich, unless otherwise stated. Phusion DNA polymerase, as well as all restriction endonucleases, T4 DNA ligase, shrimp alkaline phosphatase (rSAP) and Gibson Assembly cloning kit, were purchased from New England Biolabs. Zymolyase 20T was purchased from MP Biomedicals, 5-fluoroorotic acid was purchased from Thermo Fisher Scientific. Streptomyces strains were grown on soya flour mannitol (SFM) agar medium (20 gL -1 soya flour, 20 gL -1 mannitol, 20 gL -1 agar), with appropriate antibiotic selection upon insertion of plasmid DNA (50 µg mL -1 apramycin when transformed with pCRISPomyces2-derived plasmids; 25 µg mL -1 kanamycin when transformed with pCAP03-derived plasmids; 25 µg mL -1 nalidixic acid on the first round of subculture after intergenic conjugation). E. coli ET12567 and ET12567/pUB307 were used for the purpose of intergenic tri-parental conjugation. One Shot TOP10 chemically competent E. coli cells (Thermo Fisher Scientific) were used for cloning and storage of plasmid DNA. All E. coli strains were grown on lysogeny broth (LB) medium (10 gL -1 tryptone, 5 gL -1 yeast extract, 10 gL -1 NaCl) or LB agar medium (same as LB medium, with 15 gL -1 agar), with appropriate antibiotic selection (50 µg mL -1 apramycin when transformed with pCRISPomyces2-derived plasmids, 25 µg mL -1 chloramphenicol to maintain the dam mutation in E. coli ET12567, 25 µg mL -1 kanamycin either to maintain helper plasmid pUB307 or after insertion of pCAP03-derived plasmids).
Culturing and engineering of microorganisms
S. cerevisiae VL6-48N was used for TAR cloning and grown on yeast extract peptone (YPD) broth (5 gL -1 yeast extract, 10 gL -1 peptone, 2% w/v glucose) or YPD agar (same as YPD, with 15 gL -1 agar). Purification of genomic DNA from S. sclerotialus was performed from a 100-mL liquid culture by phenol-chloroform extraction. 9 The scl gene cluster was captured using TAR cloning. 23 Assembly of plasmid pCAP03-scl was performed following the procedure described by Moore and colleagues; pCAP03 was a gift from Bradley Moore (Addgene plasmid # 69862). 24 For this purpose String DNA fragments (Thermo Fisher Scientific) were ordered to include 60-bp hooks homologous to either side of the scl cluster ( Supplementary Table S2 ) and introduced into pCAP03
via Gibson Assembly (New England Biolabs). The identity of the captured cluster was confirmed by PCR amplification and restriction digestion (Supplementary Figure S17) .
Insertion of the scl gene cluster in the genome of the heterologous hosts S. albus and S. coelicolor was accomplished via intergenic tri-parental conjugation following the protocol described by Moore and colleagues. 24 CRISPR/Cas9-based engineering of S. albus strains was performed using plasmids pCm2-sclM4, pCm2-sclN, pCm2-sclA and pCm2-sclQ1-4. Golden Gate Assembly was first performed to insert the specific sgRNAs into the backbone pCm2 plasmid, then Gibson Assembly was used to include 800-bp homologous recombination arms, all following the procedure described by Zhao and colleagues (see Supplementary Table S3 for plasmids description); pCRISPomyces-2 was a gift from Huimin Zhao (Addgene plasmid # 61737). 15 Clearance of temperature sensitive plasmids based on pCm2 was achieved by culturing the mutant strains on SFM agar medium non-selectively at 39°C. The ethyl acetate was removed under reduced pressure and the sample re-dissolved in deuterated methanol for NMR analysis.
MIC testing
The susceptibility of bacterial strains was investigated in collaboration with the Warwick 
